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Abstract
Background: Peutz-Jeghers syndrome (PJS) is a rare autosomal dominantly inherited disease characterized by
gastrointestinal hamartomatous polyposis and mucocutaneous pigmentation. The genetic predisposition for PJS
has been shown to be associated with germline mutations in the STK11/LKB1 tumor suppressor gene. The aim of
the present study was to characterize Hungarian PJS patients with respect to germline mutation in STK11/LKB1 and
their association to disease phenotype.
Methods: Mutation screening of 21 patients from 13 PJS families were performed using direct DNA sequencing
and multiplex ligation-dependent probe amplification (MLPA). Comparative semi-quantitative sequencing was
applied to investigate the mRNA-level effects of nonsense and splice-affecting mutations.
Results: Thirteen different pathogenic mutations in STK11, including a high frequency of large genomic deletions
(38%, 5/13), were identified in the 13 unrelated families studied. One of these deletions also affects two
neighboring genes (SBNO2 and GPX4), located upstream of STK11, with a possible modifier effect. The majority of
the point mutations (88%, 7/8) can be considered novel. Quantification of the STK11 transcript at the mRNA-level
revealed that the expression of alleles carrying a nonsense or frameshift mutation was reduced to 30-70% of that
of the wild type allele. Mutations affecting splice-sites around exon 2 displayed an mRNA processing pattern
indicative of co-regulated splicing of exons 2 and 3.
Conclusions: A combination of sensitive techniques may assure a high (100%) STK11 mutation detection
frequency in PJS families. Characterization of mutations at mRNA level may give a deeper insight into the
molecular consequences of the pathogenic mutations than predictions made solely at the genomic level.
Background
Peutz-Jeghers Syndrome (PJS) is a rare autosomal-domi-
nant hereditary condition with incomplete penetrance,
characterized by hamartomatous polyps of the gastroin-
testinal tract and pigmented lesions of the buccal
mucosa, perioral region and other sites [1,2]. PJS
patients have an increased risk of cancer of multiple
locations, predominantly the colon, small intestine, sto-
mach, esophagus, pancreas, breast, ovary and uterine
cervix [3-6].
This condition is primarily associated with germline
mutations in the serine/threonine kinase 11 (STK11/
LKB1) gene, localized on the chromosomal segment
19p13.3 [7,8]. The gene spans 23 kb, consists of nine
coding exons and a final noncoding exon [9,10]. The
protein it codes for plays a role in cellular energy meta-
bolism, cell polarization, p53-dependent apoptosis,
VEGF regulation and Wnt signal transduction [11-14].
T h ep r e v a l e n c eo fg e r m l i n ep a t h o g e n i cSTK11 point
mutations in PJS cases has been reported with very dif-
ferent frequencies, ranging from about 90% to only 10%
[9,10,15], depending on both patient selection criteria
and the screening methods used. The low point muta-
tion rates reported in some studies raised the possibility
of the existence of another PJS susceptibility gene, a
notion investigated by genetic linkage analyses in PJS
families [16,17]. An alternative hypothesis, offering an
explanation for the absence of STK11 mutations in PJS
families in some studies, is the existence of alterations
not detectable by the conventional mutation screening
methods used. Multiplex Ligation-dependent Probe
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and easy-to-perform approach to scan for large genomic
deletions, and this type of mutation was indeed shown
to have a significant contribution to the STK11 muta-
tion pattern [18-20]. Taken together, STK11 aberrations
seem to date to account for almost all familial PJS cases,
bringing the existence of genetic heterogeneity into
question.
We report here the clinicopathological manifestation
and results of a comprehensive mutation analysis of the
STK11 gene in 13 unrelated PJS families. We describe a
number of novel mutations in PJS patients comprising
the largest number of patients from the Central-Eastern
European region reported so far.
Methods
Patients and samples
Individuals in this study were referred for genetic coun-
seling and testing to the Department of Molecular
Genetics at the National Institute of Oncology, Buda-
pest, Hungary between 1995 and 2008. All investigations
have been carried out in compliance with internationally
recognized guidelines. Study protocols have been
approved by the Institutional Ethical Board. Written
informed consent was obtained from each patient.
Included in this study were 21 patients from 13 Peutz-
Jeghers families.
Mutation analysis
DNA was extracted from blood samples of all consent-
ing subjects using the classic phenol-chloroform
method. The entire coding region and splice junctions
of the STK11 gene were amplified by PCR (primer
sequences are available upon request). Systematic muta-
tion screening was performed using direct bidirectional
sequencing applying an ABI 3130 Genetic Analyzer
(Applied Biosystems). The presence of all mutations was
confirmed using a different blood sample.
Additionally, the coding region of STK11 was
screened for genomic aberrations using the MLPA Kit
P101 (MRC-Holland), according to the manufacturer’s
recommendations, and as described previously [21].
For the determination of the exact lengths of deletions
having both breakpoints within the gene, we applied a
combination of XL-PCR and sequencing. Since the
various deletions detected all required individual
approaches to determine the exact length of the dele-
tion, a detailed description is outlined for each of them
in the legends of the figures (Additional files 1 and 2:
Figures S1 and S2).
To assess the approximate length of deletions extend-
ing over the 5’ gene boundaries, the sequence copy
number at multiple sites upstream of STK11 was deter-
mined. Gene dosage assays were performed in triplicates
using the Power SYBR Green PCR Master Mix on an
ABI Prism 7900 HT Sequence Detection System
(Applied Biosystems). The conditions for thermal
cycling were 50°C for 2 min and 95°C for 10 min, fol-
lowed by 40 cycles of 95°C for 15 sec and 60°C for
1 min. The regions used for copy number testing were
16.4 kb, 31.6 kb, 99.4 kb, 110.5 kb, and 120.1 kb
upstream of the STK11 gene, all selected from non-
repetitive regions. Primer sequences and localization
data are given in Additional file 3: Table S1. The ratio
changes between these 5’ and known two-copy regions
were calculated by the 2
-ΔΔCt method [22] using muta-
tion-negative samples for calibrations after ensuring that
amplification efficiencies of the control and target
amplicons were comparable.
The mutation nomenclature used here complies with
the recommendations of den Dunnen and Antonarakis
[23,24], sequence variations are named in relation to the
ATG codon in cDNA reference sequence NM_000455.4,
and predicted changes at the protein level are given
according to the protein reference sequence NP_000446.1,
as detailed on the website of the Human Genome Varia-
tion Society [25].
Expression analysis
We performed RNA extraction from blood leukocytes of
mutation carriers using the RNAqueous Kit, and carried
out cDNA synthesis starting from 400 ng of total RNA
using the High-Capacity cDNA Reverse Transcription
Kit according to the manufacturer’s instructions
(Applied Biosystems). In order to assess the effects of
the mutations at the mRNA level, we sequenced the
cDNA of carrier individuals and estimated the expres-
sion levels of the mutant alleles by comparing the area-
under-the-curve ratios at heterozygous mutation posi-
tions, using the genomic DNA sample as calibrator.
Statistical analysis
Differences between groups were calculated using a Stu-
dent’st - t e s t ,w i t hpv a l u e sl e s st h a n0 . 0 5c o n s i d e r e d
significant.
Results
Patient characteristics
A total of 13 probands and 8 affected relatives with a
history of Peutz-Jeghers syndrome (PJS) were included
in this study. The disease was diagnosed at an average
age of 21.9 years (within a range of 3-51 years). All but
one of the probands showed the classical PJS phenotype
of buccal freckling and hamartomatous polyps; one pro-
band (HP09), diagnosed at 35 years of age, showed no
typical mucocutaneous pigmentation. From the 13 pro-
bands only 8 had a family history of the disease, while
the remaining 5 cases (38%) appeared to be the result of
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Page 2 of 9de novo mutations. These two groups showed no signifi-
cant difference in their average age of disease onset
(20.7 years for those with family history versus 22.2
years for the suggested de novo mutation carriers; p =
0.41). Clinical characteristics of the patients in this
study are detailed in Table 1.
Germline mutations
From the 13 unrelated families enrolled in this study, 13
distinct pathogenic mutations were indentified. These
included three one-base deletions leading to frameshifts,
three nonsense base changes, two substitutions affecting
splice sites and five genomic deletions removing one to
seven exons; three of this latter type of aberrations
extended into the upstream genomic regions of the
STK11 gene (Table 2), one of them also affecting two
neighboring genes (SBNO2 and GPX4). A schematic
representation of the mutations uncovered is presented
in Figure 1, showing that all of them affect the kinase
domain of the protein.
Reduced mRNA expression level of the mutant allele
was observed for all cases carrying point mutations
causing premature stop codons (small deletions and
nonsense changes). This reduction of allelic expression
showed a broad range (30-70% mutant allele level in
cDNA, as compared to the corresponding genomic
DNA) and was more prominent for the new acquired
stop codons closer to the 3’ end of the gene. Interest-
ingly, the three mutations (c.540delG, c.550delC and
c.801delC) giving rise to the same premature stop
codon (in exon 6) also showed a comparatively wide
spectrum of decrease in the expression of the mutant
allele (30-60%) (Figure 2).
Bioinformatics analysis predicted the two splice-site
affecting mutations (c.291-2A>T and c.597 + 1G>A) to
abrogate normal splicing (a decrease in splice site score
from 9.4 to 1.6 for the 3’ site in intron 1 and from 6.5
to 4.2 for the 5’ site in intron 4 as calculated by the
online tool hosted by the Zhang Lab [26]). Indeed,
cDNA analysis revealed that the intron 4 nucleotide
substitution results in skipping of exon 4, while the
c.291-2A>T mutation resulted in a loss of both exons 2
and 3, demonstrated at the cDNA level (data not
shown).
In the cases with genomic deletions where both 5’ and
3’ breakpoints were situated within the gene, junction
determination revealed different sequence features at
the boundaries. The deletion encompassing exons 2-3 in
Table 1 Clinical characteristics of patients diagnosed with Peutz-Jeghers syndrome
Family Patient Gender
a Age
b Localization
c Polyp count PP
d Family history
HP01 4688 F 29 SB 40-50 + dizygotic twins
4689 F 29 SB 60-70 +
HP02 6107 M 33 SB 7 + -
HP03 6202 M 24 SB <10 + uncle &
6135 M 13 SB <10 + nephew
HP04 6213 M 22 ST;SB >100 + -
HP05 6456 F 22 CR <10 + mother &
6457 F 8 ST 1 + daughter
HP06 6453 F 11 ST;SB;CR <50 + -
HP07 6525 M 10 ST;SB;CR >100 + -
HP08 6782 M 27 ST <10 + son &
6783 F 31 SB <10 - mother
HP09 6853 M 35 ST;SB;CR >100 - -
HP10 7081 M 3 ND ND + father &
7082 F 4 ND ND + daughter
HP11 7132 F 14 SB >10 + siblings
7130 F 11 SB;CR >10 ND
HP12 5829 F 26 SB <50 + mother &
5116 F 11 SB <10 + daughter
HP13 6800 F 51 SB;CR >10 + mother &
6799 M 28 SB 2 + son
a: F = female; M = male
b: Age at diagnosis (years)
c: Polyp localization, CR = colorectum; SB = small bowel; ST = stomach
d: presence of perioral pigmentation
ND: no available data
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nation between two Alu elements in the same strand
(AluJr in intron 1/AluY in intron 3). The breakpoints of
the other deletion (removing exons 3-7 in HP10) are
not localized to Alu elements or any other repetitive
sequences, but revealed the addition of one nucleotide
at the junction site, (close to but not within a microho-
mology). See Additional files 1, 2, 4 and 5: Figures S1,
S2, S3 and S4) for more details on the determination of
genomic deletion breakpoints.
Interestingly, cDNA analysis of these cases with dele-
tions showed a splicing pattern of exon 2-3 skipping on
cDNA of HP01, confirming the alteration seen at the
genomic (DNA) level. For the carrier of the genomic
deletion of exons 3-7 we found that exons 2 to 7 were
skipped from the cDNA, inconsistent with the initial
prediction of exon 3-7 cDNA loss (Figure 3).
Discussion
In most previous studies germline STK11 mutations
were found in 50-90% of PJS patients [20,27]. In this
study we identified deleterious sequence alterations in
all 13 PJS families studied, including point mutations
(8/13, 62%) as well as large genomic deletions removing
from one to several exons of the gene (5/13, 38%). This
high fraction of large genomic aberrations identified in
Hungarian patients is in agreement with the proportions
seen in several other populations [18,19,28,29]. Only
one of the point mutations uncovered in our cohort
(c.180C>A; p.Tyr60X) can be found in the publicly
available version of The Human Genome Mutation
Database [30,31], all other point mutations can be con-
sidered novel. The novel or recurrent status of the large
genomic deletions cannot be safely assessed, since the
exact breakpoint sequences of these are usually left uni-
dentified in the literature except for in two very recent
publications [32,33]. According to these cited studies,
Alu elements show a striking overrepresentation in the
genomic region where STK11 resides, and play a major
role in its instability, although deletion mechanisms not
involving repetitive elements are also common [32,33].
Our data are in line with these recent results, since out
of the two deletions for which we were able to deter-
mine the breakpoints, one junction involved two Alu
elements with a 26 bp perfect homology, suggesting the
mechanism of homologous recombination. The other
deletion showed the insertion of one nucleotide at the
junction site, which is a common feature of NHEJ
repair. Unfortunately, we could not determine the exact
breakpoints of the other deletions due to the difficulties
in amplifying the GC- and repeat-rich regions involved.
The extent of large genomic aberrations involving
other tumor suppressor genes is also only rarely deter-
mined, although these deletions may affect other neigh-
boring genes having a potential phenotype-modifying
effect [33-35], sometimes even raising the possibility of
novel mutation mechanisms [36]. In our PJS families,
out of the 5 large deletions one extended into the cod-
ing region of other genes situated upstream of STK11,
as determined by copy-number assays at specific geno-
mic loci. In this case (HP13), the deletion affected the 5’
genes SBNO2 and GPX4, but did not reach the next
upstream gene POLR2E. The gene SBNO2, a component
of the IL-10-mediated anti-inflammatory pathway [37]
has currently no known association with gastrointestinal
diseases [33], but it was affected together with STK11 in
several cell lines investigated [38,39]. Also, interleukin
and JAK-STAT signaling, in which SBNO2 plays a role
[37], is widely implicated in gastrointestinal cancers.
Interestingly, a polymorphism at the 3’ UTR of the glu-
tathione peroxidase GPX4 was recently reported as a
risk-modifier for colorectal cancer [40], the allele
Table 2 Germline STK11 mutations in PJS patients
Family Exon/Intron Mutation name Mutation type
a Effect on cDNA or mRNA/protein level
b
HP01 ex 2-3 c.291-5484_464+384del6865 GD exon 2-3 skipping
HP02 ex 6 c.801delC FS p.Ile267MetfsX20
HP03 ex 1 c.1-?_290+?del GD (no start; 1 allele)
HP04 ex 1 c.180C>A NS p.Tyr60X
HP05 ex 7 c.876C>G NS p.Tyr292X
HP06 ex 1 c.142A>T NS p.Lys48X
HP07 ex 4 c.550delC FS p.Leu184SerfsX103
HP08 in 1 c.291-2A>T SS exon 2-3 skipping
HP09 ex 4 c.540delG FS p.Asn181ThrfsX107
HP10 ex 3-7 c.375-106_921-264del3504insA GD exon 2-7 skipping
HP11 ex 1-3 c.1-?_464+?del GD (no start; 1 allele)
HP12 in 4 c.597+1G>A SS exon 4 skipping
HP13 ex 1-7 c.1-?_920+?del GD (no start; 1 allele)
a: GD = genomic deletion; FS = frameshift mutation; NS = nonsense mutation; SS = splice-site mutation
b: predicted effects are shown in brackets; mutation effect on mRNA-level disagreeing with previous predictions are shown in italics
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Page 4 of 9Figure 1 Germline mutations in the STK11 gene. Panel A shows the mutations within the gene: exon structure of the STK11 gene is at the
top, the coding region is shown in blue. The introns are not drawn to scale. The locations of point mutations are marked by red arrowheads;
the intragenic large deletions are depicted as red rectangles below the gene. The approximate localization of large deletions extending
outwards STK11 is portrayed on Panel B. The known RefSeq genes of the region are shown as filled arrows. The minimal and maximal sizes of
the large genomic deletions are indicated as red and pink bars, respectively. The loci where copy number analyses were done are marked by
vertical green arrows, names reflecting their localization with respect to the STK11 gene. Panel C shows the data of the gene dosage
experiments.
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lower cancer risk. Taking these results into account, it is
possible that the complete inactivation of one allele of
this gene by a deletion may have a similar protective
effect on the disease phenotype. Indeed, the age at dis-
ease onset was higher for both affected members of the
HP13 family (28 and 51 years of age) as compared to
the average age of onset of all other PJS patients (19.1
years), but no other specific feature was detected. Our
results are comparable with those reported by Le Meur
and co-workers [41], who characterized a large genomic
deletion in one family completely removing one copy of
Figure 2 Demonstration of the decreased expression of alleles carrying nonsense and frameshift mutations. Panel A shows the results
of semiquantitative sequencing of six STK11 mutations. The relative expression of the mutant allele (based on area-under-the-curve
measurements, AuC) is shown in relation to the nucleotide position of the newly acquired stop codon. An example of AuC measurement is
shown on Panel B. The genomic DNA and cDNA sequencing electrophoretograms of a c.801delC mutation carrier sample (HP02) is presented,
with the AuC base ratio as well as the ratio change (cDNA compared to gDNA) given below for the nucleotide position marked by an asterisk.
Figure 3 PCR analysis and sequencing results of the proband of family HP10 presenting with a large genomic deletion encompassing
exons 3-7. Panel A shows the results of the PCR amplification of the cDNA sample of the mutation carrier along with samples from two
negative controls (designated as ‘neg’), using a sense primer in exon 1 and an antisense primer in exon 8. The extra band in the mutation carrier
sample (marked by a red arrow) indicates the presence of a variant mRNA species resulting from fusion of exon 1 to exon 8. Faint bands on the
gel are most likely the results of heteroduplex molecules. MW: molecular weight marker; neg: mutation negative samples. The sequencing result
illustrating the skipping of exons 2-7 is shown on Panel B with the sequences of the normal as well as the mutant allele given below the
sequenogram.
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(including GPX4). In that study, two relatives of the pro-
band were diagnosed with PJS at the relatively late age
of 43 years, suggesting a potential modifier role for
GPX4 in PJS.
In order to assess the potential of aberrant STK11
mRNA species to produce truncated proteins in blood
leukocytes, we determined the allelic ratio of mutation
carrier transcripts by semi-quantitative sequencing and
found that their amount ranged from ~30-70% com-
pared to their wild-type counterpart. Despite the semi-
quantitative nature of this method, our results are
similar to those obtained by other groups examining
mutated alleles of several different genes [42,43].
The reduction of the level of premature stop codon-
containing transcripts is partially attributable to the
mechanism of nonsense-mediated mRNA-decay, an evo-
lutionarily conserved mechanism distinguishing normal
from premature termination codons on the basis of
their location with respect to exon-exon junctions, and
targeting the latter for degradation [44]. Moreover, the
fact that three different frameshift mutations giving rise
to the same early stop codon presented with highly dis-
similar levels of the mutant allele either reflects on the
inter-individual variability in NMD efficiency [45-47], or
it may imply that mechanisms other than nonsense-
mediated mRNA decay play a role in determining the
fate of these transcripts.
Another mechanism preventing the emergence of trun-
cated Stk11 protein forms is that most known STK11
mutations, and all mutations mentioned in the present
study, destroy the kinase domain of the protein, which in
turn prevents the binding of Hsp90 and Cdc37, two pro-
teins indispensable for stabilizing Stk11 [48,49].
Aside from the decreased stability of the mutant tran-
scripts, mRNA-level characterization of the carriers’ sam-
ples revealed another interesting feature. The effect of
the c.291-2A>T mutation destroying the consensus
sequence of the intron 1 splice acceptor site was pre-
dicted to be the loss of exon 2, but both exons 2 and 3
were skipped in the mutant mRNA; likewise, the genomic
deletion of exons 3-7 caused exon 2-7 skipping. This pat-
tern of closely coupled splicing of two adjacent exons
might be associated with the fact that the second intron
of STK11 is processed by the minor U12-dependent spli-
ceosome [50]. Moreover, the linked skipping of exon 2
and 3 seems to be an evolutionarily conserved phenom-
enon, since this isoform is the most prominent alterna-
tively spliced STK11 mRNA species listed in The
Alternative Splicing and Transcript Diversity Database
for both men and mice [51,52]. Its protein product has
been shown to be catalytically inactive and to reside
exclusively in the nucleus, in contrast to the diverse
cellular localization of full-length Stk11 [48].
Conclusions
In summary, the high detection rate of mutations in our
study underlies the importance of using a combination
of techniques, preferably direct sequencing and MLPA,
for STK11 germline mutation screening in PJS patients.
Analysis of mRNA also seems to be crucial to appropri-
ately assess the consequences of mutations which may
not be straightforward from bioinformatics predictions
only. Our results support the idea that elucidating the
role of the GPX4 gene and potentially also the SBNO2
as modifiers in PJS or in PJS-associated tumors would
be of high interest.
Additional material
Additional file 1: XL-PCR analysis of two samples carrying the
genomic deletion of exons 2-3 of the STK11 gene. The results of the
XL-PCR amplification of the genomic deletion is shown.
Additional file 2: Determination of the length of the genomic
deletion removing exons 3-7 of the STK11 gene. The results of the
MLPA and PCR analyses of the genomic deletion is shown.
Additional file 3: Primers used for dosage assays. Primer sequences
and localization information is given for all amplicons used for dosage
assays of chromosome regions upstream of the STK11 gene.
Additional file 4: Breakpoint sequence of the genomic deletion
removing exons 2-3 of the STK11 gene. The genomic deletion
breakpoint is shown on a sequencing chromatogram with additional
information on the repetitive elements involved in the deletion.
Additional file 5: Breakpoint sequence of the genomic deletion
removing exons 3-7 of the STK11 gene. The genomic deletion
breakpoint is shown on a sequencing chromatogram with additional
information on the sequence elements involved in the deletion.
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